• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA approves first equine injectable for fever control

November 27, 2019

Zimeta has been associated with rapid and effective reduction of pyrexia in horses.

Biopharmaceutical company Kindred Biosciences announced this week that the FDA has approved Zimeta (dipyrone injection) for the control of fever (pyrexia) in horses.

Zimeta, which belongs to the pyrazolone class of nonsteroidal anti-inflammatory drugs (NSAIDs), is the first FDA-approved injectable medication for equine fever control. It is intended for intravenous injection once or twice daily (no more frequently than every 12 hours) for up to three days at a dose of 30 mg/kg (13.6 mg/lb). The drug may be readministered for up to three days based on recurrence of fever.

In a well-controlled clinical study, Zimeta administration resulted in rapid and effective fever reduction in horses with naturally occurring fever, according to a company release. More than 1 million of the 8 million horses in the U.S. receive veterinary care for fever each year, according to the release.

Zimeta is for use in horses only; its use in breeding or in pregnant or lactating mares has not been evaluated. Zimeta is not for use in humans due to the potential risk for agranulocytosis (see sidebar). Additionally, the drug is not for use in horses intended for human consumption or in food-producing animals, including lactating dairy animals.

Dipyrone: Not for people anymore

Advertisement

In several countries, including the United States, people are prohibited from taking dipyrone (also known as metimazole). In 1977, the FDA withdrew its approval of all dipyrone-containing drugs for use in humans after reports of agranulocytosis in treated patients surfaced. Agranulocytosis is a serious and potentially life-threatening blood cell deficiency that can increase one's vulnerability to infection.

Although no data indicate that agranulocytosis occurs in horses treated with Zimeta, owners, handlers and veterinary caretakers should take the necessary precautions to prevent accidental self-injection.

As a class, NSAIDs have been associated with gastrointestinal, renal and hepatic toxicity as well as coagulopathies. The most commonly reported adverse reactions in clinical trials for Zimeta include gastric ulcers, abnormal feces and prolongation of coagulation parameters Horses being treated with Zimeta should be monitored for signs of lack of appetite, diarrhea or unexplained bleeding. Caution should also be used in horses at risk for hemorrhage.

To find out more about his drug, click here.

Related Content:

ProductsEquine MedicineBreaking NewsEquine
Enhanced pet health and wellness app now available
Enhanced pet health and wellness app now available
UC Davis corrects horse’s irregular heartbeat with electrical shock procedure
UC Davis corrects horse’s irregular heartbeat with electrical shock procedure
AI-enhanced MyLabX90VET ultrasound system unveiled
AI-enhanced MyLabX90VET ultrasound system unveiled

Advertisement

Latest News

Oldest aardvark in Europe passes away

Integrative approach to treating Giardia lamblia infections

Innovative digital microscopy platform is launched

Enhanced pet health and wellness app now available

View More Latest News
Advertisement